Apyx Medical Corporation reported second-quarter 2026 total revenue of $13.9 million, a 22% increase from the prior year, driven by 28% growth in its Surgical Aesthetics segment. Surgical Aesthetics revenue reached $12.4 million, fueled by sales of the AYON Body Contouring System, increased international generator sales, and higher domestic single-use handpiece volume, while OEM segment revenue declined 12% to $1.5 million. Net loss attributable to stockholders narrowed to $3.2 million, or $0.07 per share, from $3.8 million, or $0.09 per share, and adjusted EBITDA loss improved to $0.7 million from $2.0 million. The company reaffirmed its full-year 2026 total revenue guidance of $59.0 million to $60.0 million, with Surgical Aesthetics expected to contribute $54.0 million to $55.0 million and OEM approximately $5.0 million. Apyx Medical also highlighted the limited launch of a power liposuction handpiece for the AYON platform following expanded FDA clearance, with initial commercial shipments in June 2026.
Apyx Medical IncQ2 revenue up 22%, net loss narrowed, and reaffirmed 2026 guidance
